TriSalus Life Sciences
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Employees
- 112
- Market Cap
- -
- Website
- https://trisaluslifesci.com
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Phase 1
Recruiting
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- Biological: anti-PD-1
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05607953
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Phase 1
Active, not recruiting
- Conditions
- Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05220722
- Locations
- ๐บ๐ธ
University of Colorado, Aurora, Colorado, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธColumbia University, New York, New York, United States
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1
Active, not recruiting
- Conditions
- Metastatic Uveal Melanoma in the Liver
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- TriSalus Life Sciences, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04935229
- Locations
- ๐บ๐ธ
UCLA, Los Angeles, California, United States
๐บ๐ธStanford, Stanford, California, United States
๐บ๐ธWashington University, Seattle, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath